CN102204913A - Application of ligustrazine derivative to preparation of medicament for treating melanoma - Google Patents
Application of ligustrazine derivative to preparation of medicament for treating melanoma Download PDFInfo
- Publication number
- CN102204913A CN102204913A CN2011100830884A CN201110083088A CN102204913A CN 102204913 A CN102204913 A CN 102204913A CN 2011100830884 A CN2011100830884 A CN 2011100830884A CN 201110083088 A CN201110083088 A CN 201110083088A CN 102204913 A CN102204913 A CN 102204913A
- Authority
- CN
- China
- Prior art keywords
- cell
- company
- model
- misc
- feature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DLCVYRQRINMKBM-UHFFFAOYSA-N Cc1nc(CO)c(C)nc1CO Chemical compound Cc1nc(CO)c(C)nc1CO DLCVYRQRINMKBM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of pharmacy and discloses the application of a ligustrazine derivative (2,5-dimethylol-3,6-dimethylpyrazine) to the preparation of an anti-malignant melanoma medicament. The chemical name of the ligustrazine derivative is 2,5-dimethylol-3,6-dimethylpyrazine, wherein the molecular formula is C8H12N2O2. Researches show that the ligustrazine derivative can inhibit the multiplication of melanoma cells (B16F10) and induce cell apoptosis and the like, and can be applied to the anti-malignant melanoma medicament.
Description
Technical field
The present invention relates to a kind of chemistry and be called 2,5-dihydroxymethyl-3, the ligustrazine derivant (H of 6-dimethyl pyrazine
168), especially relate to H
168Application in the anti-malignant melanoma medicine of preparation.
Technical background
Malignant melanoma also claims malignant melanoma, is a kind of malignant tumor that comes from epidermal melanin cell or nevus cell nevus, accounts for the 1-3% of all malignant tumor.The data of announcing according to World Health Organization (WHO) shows that the sickness rate of malignant melanoma worldwide shows the trend that progressively increases.Because doctor and patient are not enough to its seriousness understanding, cause this sick unsatisfactory curative effect, prognosis is relatively poor, and very easily metastasis takes place, and patient in a single day metastasis its mean survival time (MST) is taken place only is 6-9 month, and survival rate was lower than 5% in 5 years.Therefore, the medicine of developing anti-malignant melanoma has great importance.
Still do not have the melanomatous effective ways of treatment at present clinically, though chemotherapeutics has certain curative effect to malignant melanoma, toxic and side effects is big; Chinese patent medicine is generally lower to melanomatous curative effect, and curative effect is all undesirable.The melanoma medicine of clinical practice at present mostly is cytotoxic drug greatly; when suppressing tumor cell proliferation; the propagation of organism normal cell also is suppressed, and can produce harmful effect to the physiological process of normal body, so limited the clinical practice of these medicines.Therefore, exploitation high-efficiency low-toxicity, medicine that targeting is strong become the focus of melanoma drug development.
Ligustrazine (TMP) has been widely used in the clinical treatment cardiovascular and cerebrovascular disease at present as one of main effective ingredient of drug for invigorating blood circulation and eliminating stasis Rhizoma Chuanxiong.Studies show that in a large number TMP has anti peroxidation of lipid, antiinflammatory, removing free radical, antimicrobial and improves hemorheology and many-sided pharmacological actions such as antineoplastic invasion and transfer.By ligustrazine is carried out a series of structural modification and transformation, obtained the stronger ligustrazine derivant H of water solublity
168, by the screening of its pharmacological activity being found it has the effect of very strong melanoma.
Summary of the invention
The object of the present invention is to provide ligustrazine derivant (H
168) in the application of preparation in the anti-malignant melanoma medicine.
Described ligustrazine derivant code name H
168, be the derivant of alkaloid compound ligustrazine separating obtained in the Umbelliferae Ligustrum plant Rhizoma Chuanxiong, its chemical name is 2,5-dihydroxymethyl-3, the 6-dimethyl pyrazine, molecular formula is C
8H
12N
2O
2,, its structural formula is as follows:
Described H
168Application in the preparation antitumor drug, described tumor is a malignant melanoma.
This experiment shows, H
168Have good anti-malignant melanoma effect, no matter be to suppress cell proliferation, or cell death inducing all has very strong effect.Described H
168Be a kind of noval chemical compound, can be used to prepare antitumor drug with anti-malignant melanoma effect.
The present invention adopts murine melanoma high-transfer cell strain B16F10, research H
168On external cellular level, molecular level,, disclosed H to action effects such as key protein expressions in propagation, apoptosis, cell cycle arrest and the coherent signal transduction path of B16F10
168Suppress the propagation of B16F10 and induce the molecular mechanism of its apoptosis, determine the action target spot that it is possible, provide important evidence for preparing anti-malignant melanoma medicine.
Anti-malignant melanoma medicine involved in the present invention can be H
168Pharmaceutical preparation technology according to routine is prepared into a kind of suitable pharmaceutical preparation of using clinically, and possesses significant inhibition cell proliferation and apoptosis-induced curative effect.
Description of drawings
Fig. 1 H168 suppresses the B16F10 proliferation function and (compares with the blank group
*P＜0.5,
*P＜0.01)
Fig. 2 H
168Influence to B16F10 cell p21, p27, bax, bcl-2 protein expression
Fig. 3 H
168Influence (comparing * P＜0.5 with the blank group, * * P＜0.01) to B16F10 cell p21, p27, bax, bcl-2mRNA expression
The specific embodiment
Following examples are by probing into H
168In external inhibitory action to B16F10, and the anti-malignant melanoma mechanism of explaination illustrates the present invention on molecular level, but does not represent the present invention to be only limited to this embodiment.
The present invention is parent nucleus with the ligustrazine, the bromine that carries out pendant methyl replaces, obtain intermediate 2-bromomethyl-3,5, the 6-trimethylpyrazine by liquid-solid phase transfer catalysis process, Williamson reaction etc., has synthesized a series of ligustrazine derivants, by further screening, determine wherein compound H to its active anticancer
168Anti-tumor activity the strongest, and malignant melanoma had significant inhibitory effect.
Embodiment 1H
168Influence to spontaneous B16F10 melanoma metastasis model
1. experiment material
1.1 laboratory animal and cell
A cleaning level C57BL/6 mice (female, 6-8 age in week, 16-20g), Shanghai Slac Experimental Animal Co., Ltd., credit number: SCXK (Shanghai) 2007-0005; The strain of B16F10 melanoma cell, professor Xu Qiang of Nanjing University is so kind as to give.
1.2 experiment medicine
H
168, be so kind as to give by professor Li Wei of Nanjing University of Traditional Chinese Medicine; Ligustrazine hydrochloride, sweetening treatment company limited lot number in the Zhejiang Hangzhou: 20070323.
1.3 experiment reagent
DMEM (U.S. GIBCO company lot number: 1340114); PBS (laboratory self-control); calf serum (ocean, Tianjin biological product Science and Technology Ltd. lot number: QWTC0701); Trypsin (AMRESCO company lot number: 2009/08); EDTA (AMRESCO company lot number: 0105); formaldehyde (Shanghai hundred million chemical reagent company limited lot numbers of a specified duration: 20070610), normal saline (the rich pharmaceutcal corporation, Ltd of Shanghai Hua Yuanchang lot number: 070405045).
1.4 experiment equipment
Lycra inverted fluorescence microscope (German Lycra company model: DM1L), accurate pipettor (French Gilson Inc model: P2), full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020), (the safe and sound corporate system of Su Jing group is made model to superclean bench: SW-CJ-ZFD), ultra cold storage freezer (U.S. Niu Aier company model: Nu-6511), CO2 incubator (FORMA model: 3111), pure water instrument (U.S. Spring company model: S/N 020579), electronic balance (German Sai Duolisi company limited model: BT323S), desk-top electric drying oven with forced convection (the accurate experimental facilities in Shanghai company model: DHG9123A), refrigerator (Siemens Company's model: KG18V21TI), liquid nitrogen container (the CBS model: 2001), centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000).
1.5 experimental technique
The conventional B16F10 tumor cell of cultivating, preceding 4-5 days of experiment is pressed 1: 10 passage in Tissue Culture Flask.The take the logarithm cell of trophophase discards culture fluid, cleans with PBS, adds 1mL 0.25% pancreatin+0.02%EDTA Digestive system, puts into cell culture incubator, behind the 1-3min, raps culture bottle and makes cell detachment.Add 10mL DMEM, blow and beat cell, obtain single cell suspension, change the 50mL polypropylene centrifuge tube over to pipet.Centrifuge cell (1200rpm * 10min), wash twice with PBS then.Expect blue counting cells with tongue, adjusting cell concentration is 1 * 10
7/ mL.Get 50 of the heavy female C57BL/6 mices of 18～22g, be divided into 5 groups at random: the basic, normal, high dosage group of ligustrazine derivant (dosage is respectively 50mg/kg, 100mg/kg, 200mg/kg), normal saline group, ligustrazine hydrochloride group (dosage is 200mg/kg).Every mice right hind foot lift is injected tumor liquid 0.05ml down and (is contained 5 * 10
5Individual cell).Beginning in the 2nd day lumbar injection in inoculation back gives the H of corresponding dosage
168And ligustrazine hydrochloride (0.1ml/10g body weight), every day 1 time, lumbar injection successive administration 46 days.Model group gives the normal saline of corresponding dosage; Behind the inoculation tumor liquid 23 days, anesthetized mice, amputation lotus tumor lower limb, former position tumor tissues of 10% formalin fixed, take by weighing primary tumo(u)r weight and measure major axis (L1) and the longitudinal axis (L2) of primary tumor, according to the volume of following formula calculating primary tumor: 0.5236 * L1 * (L2) 2 with ruler.Administration was put to death mice after 46 days, carefully took out lung, avoided tweezers to touch the organ surface damaged tissue, and tumor nodule number and weighing lung that anatomic microscope calculates the lung surface down are heavy.
The result shows, compares H with the normal saline group
168Former position tumor for the mouse insole portion after the inoculation B16F10 melanoma cell is that volume and weight all do not have tangible influence.H
168The lung metastatic nodules that each dosage group and matched group compare the spontaneous metastasis model of melanoma obviously reduces, and significant difference (P＜0.05) is arranged, and present dosage correlation.For the heavy influence of lung, the lung of H168 administration group heavily is starkly lower than the lung heavy (P＜0.01) of matched group, but lung does not heavily have notable difference (seeing Table 1) between the various dose group.
Table 1:H
168To former position tumor growth of B16F10 and the spontaneous influence of shifting
Conclusion: this product can suppress melanomatous spontaneous the transfer and the lung transfer.
Embodiment 2H
168Influence to B16F10 melanoma cell propagation
1. experiment material
1.1 experiment is the same with cell strain
1.2 the experiment medicine is the same
1.3 experiment reagent
DMEM (U.S. GIBCO company lot number: 1340114); PBS (laboratory self-control); calf serum (ocean, Tianjin biological product Science and Technology Ltd. lot number: QWTC0701); Trypsin (AMRESCO company lot number: 2009/08) EDTA (AMRESCO company lot number: 0105); formaldehyde (Shanghai hundred million chemical reagent company limited lot numbers of a specified duration: 20070610); normal saline (the rich pharmaceutcal corporation, Ltd of Shanghai Hua Yuanchang lot number: 070405045); MTS (Promega company lot number: G111A22258402), PMS (AMRESCO company lot number: 0361).
1.4 experiment equipment
Lycra inverted fluorescence microscope (German Lycra company model: DM1L), accurate pipettor (French Gilson Inc model: P2), full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020), (the safe and sound corporate system of Su Jing group is made model to superclean bench: SW-CJ-ZFD), ultra cold storage freezer (U.S. Niu Aier company model: Nu-6511), CO2 incubator (FORMA model: 3111), pure water instrument (U.S. Spring company model: S/N 020579), electronic balance (German Sai Duolisi company limited model: BT323S), desk-top electric drying oven with forced convection (the accurate experimental facilities in Shanghai company model: DHG9123A), refrigerator (Siemens Company's model: KG18V21TI), liquid nitrogen container (CBS model: 2001), centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000), PH meter (HANNA company model: HI-221), visible-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRAMAX 190).
1.5 experimental technique
Get the good B16F10 cell of growth conditions, become cell suspension, be inoculated in 96 orifice plates 5 * 10 with trypsinization
3/ hole.Behind the conventional cultivation 24h, cell is divided into ligustrazine hydrochloride (30 μ M) matched group, adds H respectively
168, make its final concentration be respectively 0 μ M, 0.5 μ M, 2.5 μ M, 5 μ M, 10 μ M, 25 μ M, 50 μ M, 100 μ M (each 5 multiple holes), the porose 200 μ l systems that are.Dosing adds 20 μ l MTS respectively in each hole after cultivating 24h, places 37 ℃, 5%CO
2Hatch in the incubator.Measure each hole OD value at 490nm wavelength place with full-automatic microplate reader.Go out the suppression ratio of medicine on cell proliferation according to the ratio calculation of the absorbance of medicine group of being surveyed and cellular control unit, explore the influence of medicine cell growth rule.Formula is as follows: IE=1-OD
i/ OD
0, IE represents the suppression ratio of medicine on cell proliferation rate, OD
iRepresent the absorbance under certain drug level, OD
0The absorbance of expression cellular control unit.
The result shows, H
168B16F10 is had very significant inhibitory effect, and inhibitory action strengthens with the increase of drug dose, present dose-effect relationship, remarkable with the matched group comparing difference, strong in 50 and 100 μ M inhibitory action, significant difference (P＜0.01) (Fig. 1, table 2) is arranged.
Table 2:H
168Influence to B16F10 propagation
Conclusion: this product can significantly suppress the propagation of B16F10 melanoma cell.
Embodiment 3H
168Influence to the B16F10 melanoma cell cycle
1. experiment material
1.1 experiment is the same with cell strain
1.2 the experiment medicine is the same
1.3 experiment reagent
DMEM (U.S. GIBCO company lot number: 1340114); PBS (laboratory self-control); calf serum (ocean, Tianjin biological product Science and Technology Ltd. lot number: QWTC0701); Trypsin (AMRESCO company lot number: 2009/08) EDTA (AMRESCO company lot number: 0105); dehydrated alcohol (Shanghai chemical reagent company limited lot number: 20060615), cell cycle detection kit test kit (the biological company limited lot number of the triumphant base in Nanjing: KGA513).
1.4 experiment equipment
Lycra inverted fluorescence microscope (German Lycra company model: DM1L), accurate pipettor (French Gilson Inc model: P2), full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020), (the safe and sound corporate system of Su Jing group is made model to superclean bench: SW-CJ-ZFD), ultra cold storage freezer (U.S. Niu Aier company model: Nu-6511), CO
2Incubator (the FORMA model: 3111), flow cytometer (Bio Rad Laboratories).
1.5 experimental technique
With well-grown B16F10 with 0.25% trypsinization after, make cell suspension with the DMEM culture fluid, adjust cell concentration and be inoculated in 6 orifice plates 3 * 10 respectively
5Individual cells/well.Treat that cell attachment is monolayer and merges back (about 12h), abandoning supernatant is replaced by the DMEM culture fluid that contains 0.4% calf serum, and adding ligustrazine hydrochloride (30 μ M) in contrast, adds H respectively
168, make its final concentration be respectively 0 μ M, 0.5 μ M, 2.5 μ M, 5 μ M, 10 μ M, 25 μ M, 50 μ M, cultivate behind the 24h pancreatin collecting cell with 0.25%, PBS washes cell 2 times, and 70% ethanol spends the night fixing.Collect 2-3 * 10
4Cell adds dyestuff respectively by the test kit explanation, uses cells were tested by flow cytometry behind the lucifuge effect 5-15min.Experiment repeats 5 times.
The result shows, H
168The cell cycle of scalable B16F10, cell cycle is just influential when 25 μ M, and this realizes by cell was blocked in the G0/G1 phase that mainly G2/M phase and S phase cell reduce simultaneously.This effect has concentration dependent, and when effect concentration when reaching 50 μ M, but appreciable impact cell cycle and matched group are compared and had significant difference (table 3).
Table 3:H
168Influence to the B16F10 cell cycle distribution
Conclusion: this product can the melanomatous cell cycle of appreciable impact B16F10.
Embodiment 4H
168Influence to B16F10 melanoma cell apoptosis
1. experiment material
1.1 experiment is the same with cell strain
1.2 the experiment medicine is the same
1.3 experiment reagent
DMEM (U.S. GIBCO company lot number: 1340114), PBS (laboratory self-control), calf serum (ocean, Tianjin biological product Science and Technology Ltd. lot number: QWTC0701), Trypsin (AMRESCO company lot number: 2009/08) EDTA (AMRESCO company lot number: 0105), Annexin V-FITC apoptosis test regent box (Nanjing triumphant base biological).
1.4 experiment equipment is the same
1.5 experimental technique
The cell of B16F10 is handled the same, and with the pancreatin collecting cell that does not contain EDTA, PBS washes cell 2 times behind the cultivation 24h, collects 1-5 * 10
5Cell adds dyestuff respectively by the test kit explanation, uses cells were tested by flow cytometry behind the lucifuge effect 15min.Experiment repeats 3 times.
The result shows, H
168Can obviously promote the B16F10 apoptosis, compare H with matched group
168Promote that when 10 μ M apoptosis just has difference, P＜0.05), when reaching 50 μ M, concentration has significant difference (P＜0.01) (table 4).
Table 4:H
168To B
16F
10The inhibition of proliferation rate
Conclusion: this product can significantly promote the apoptosis of B16F10 melanoma cell.
Embodiment 5H
168Influence to p21, p27, bax, bcl-2 protein expression in the B16F10 cell PI3K/Akt signal path
1. experiment material
1.1 experiment is the same with cell strain
1.2 the experiment medicine is the same
1.3 experiment reagent
DMEM (U.S. GIBCO company lot number: 1340114), PBS (laboratory self-control), calf serum (ocean, Tianjin biological product Science and Technology Ltd. lot number: QWTC0701), Trypsin (AMRESCO company lot number: 2009/08) EDTA (AMRESCO company lot number: 0105), dehydrated alcohol (Shanghai chemical reagent company limited lot number: 20060615), BCA test kit (PIERCE Lot.EF60968), Bcl-2/Bax Antibody (Santa cruz), P21/P27Antibody (Santacruz), β-actin monoclonal antibody (Bioworld, Cat No.:MB2237), Goat anti-RabbitIgG (H﹠amp; L)-HRP (Bioworld).
1.4 experiment equipment
Lycra inverted fluorescence microscope (German Lycra company model: DM1L), accurate pipettor (French Gilson Inc model: P2), full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020), (the safe and sound corporate system of Su Jing group is made model to superclean bench: SW-CJ-ZFD), ultra cold storage freezer (U.S. Niu Aier company model: Nu-6511), CO
2Incubator (FORMA model: 3111), electrophresis apparatus (Liuyi Instruments Plant, Beijing's model: DYY-C), electrophoresis tank (Bio-Rad), electric-heated thermostatic water bath (the last grand experimental facilities company limited of Nereid model: DK-8D), ice machine (the SCORTSMAN model: AF10) PVDF western blot film (Roche company article No.: 3010040), X-mating plate (Kodak company) etc.
1.5 experimental technique
The B16F10 cell of phase of taking the logarithm makes 1 * 10 with 0.25% trypsinization
6/ ml cell suspension respectively adds 1ml cell suspension (10ml system) in diameter is the culture dish of 90mm.Be changed to the culture medium that contains 0.4% calf serum behind the 24h and add medicine, make the medicine final concentration be respectively 0,10,30,50,70 μ M, and with ligustrazine hydrochloride (30 μ M) in contrast, 37 ℃, 5%CO
2Incubator extracts albumen and adopts the BCA method to measure protein concentration (seeing description) after cultivating 24h.Get sample on the 50 μ g after the degeneration, concentrate every glue of gel electrophoresis: 0.02A,, forward on the nitrocellulose filter afterwards to the bromophenol blue disappearance with 10% separation gel, 5%.Westem blot detects the expression of p21, p27, bax, bcl-2, an anti-P21, P271: 200; One anti-Bcl-2, Bax 1: 200; β-actin 1: 10000 adds the goat anti-rabbit igg (1: 20000) of horseradish peroxidase-labeled after 4 ℃ of overnight incubation.Press 0.1ml/cm
2Add chemical illuminating reagent.Use the Kodak film exposure; Make confidential reference items with β-actin.
The result shows H
168Can influence the B16F10 cell proliferation by influencing the proteic expression of p21/p27, by influencing the proteic induced expression B16F10 of Bax, Bcl-2 apoptosis.Along with the increase of drug level, the proteic expression showed increased of p21/p27, and the downward modulation of Bcl-2/Bax ratio shows H
168Thereby can suppress the B16F10 cell proliferation by influencing these proteic expression, induce its apoptosis (Fig. 2).
Conclusion: this product can suppress the propagation of B16F10 melanoma cell, induces its apoptosis simultaneously.
Embodiment 6H
168Influence to P21, P27, Bax, Bcl-2mRNA expression in the PI3K/Akt signal path in the B16F10 cell
1. experiment material
1.1 experiment is the same with cell strain
1.2 the experiment medicine is the same
1.3 experiment reagent
DMEM (U.S. GIBCO company lot number: 1340114), PBS (laboratory self-control), calf serum (ocean, Tianjin biological product Science and Technology Ltd. lot number: QWTC0701), Trypsin (AMRESCO company lot number: 2009/08) EDTA (AMRESCO company lot number: 0105), SYBR Premix Ex Taq (Perfect Real Time) (TaKaRa), TrizolReagent (Invitrogen, Cat.NO.:15596-026), isopropyl alcohol (Shanghai chemical reagent company limited, lot number: 2007031028), chloroform (Chemical Reagent Co., Ltd., Sinopharm Group, lot number: 10006818), dehydrated alcohol (Shanghai pilot scale chemical corp, lot number: 2008072312), DEPC (Amresco, lot2010/11); OligodT (15), 5*M-MLV buffer, dNTP Mix, M-MLV, RNase inhibitor, Taq DNA Polymerase (all available from Shanghai Shenergy Biocolor BioScience ﹠ Technology Company); DTT (Promega, Cat.NO.:P1171); 5 * M-MLV buffer (Promega, lot:23713915); SYBRPremix Ex Taq (Perfect Real Time) (TaKaRa, Cat.NO.:DRR041A), etc.
1.4 experiment equipment
Centrifuge (U.S. BECKMAN company, model: GS-15R); Microcentrifuge (U.S. BECKMAN company, model: MSD97K49), nucleic acid-protein analyser (U.S. BECKMAN company, model: DU640); Electrophoresis tank (U.S. Bio-Rad company, model: 525BR027843); (Nanjing University south reaches biotechnology development company, model: TY-80S) to shaking table; Sealing machine (Shanghai Mai Er multimachine tool company limited, model: FP-300); Developing machine (Jiangsu Province Taixing City Light Industrial Machinery Plant); The X film; Culture dish (Corning costar company, lot number: 430167); Real-time PCR instrument (Bio Rad Laboratories, IQ model); PCR manages (Bio Rad Laboratories's specification: 96 orifice plates); EP pipe, Tip some (Axygen company, 081107-213), etc.
1.5 experimental technique
The cell of B16F10 is handled the same.Detect its concentration in 260nm wavelength place after extracting total RNA with TRlzol, get 1 μ gRNA then and carry out reverse transcription.Reaction system (40 μ l) comprises OligodT (100ng/ μ l) 10 μ l, 5 * MMLV buffer, 8 μ l, dNTP (10mM) 4 μ l, MMLV (200u/ μ l) 2 μ l, RNase inhibitor 1 μ l complements to 40 μ l with the RNA enzyme aquesterilisa that goes that contains 0.1%DEPC.42 ℃, 1h; 95 ℃, 5min; 4 ℃, 5min carries out reverse transcription.Primer sequence: P21 (F:5-AGTATGCCGTCGTCTGTTCG-3; R:5-GAGTGCAAGACAGCGACAAG-3); P27 (F:5-CAGC ' ITGCCCGAGTTATA-3; R:5-TGGGGAACCGTCTGAAAC-3); Bcl-2 (F:5-ATGGGGTGAACTGGGGGATTG-3; R:5-TTCCGAATTTGTTTGGGGCAGGTC-3); Bax (F:5-GGGTGGTTGCCCTTTTCTACT-3; R:5-CCCGGAGGAAGTCCAGTGTC-3); β-actin (F:5-TGCGTGACATCAAAGAGAAG-3; R:GATGCCACAGGATTCCATA-3).
Amplification system is 20 μ l:SYBR Premix Ex TaqTM (Perfect Real Time), 10 μ l; Primer (10 μ M): each 1 μ l of upstream and downstream; Dna profiling: 2 μ l; The RNA enzyme aquesterilisa that goes that contains 0.1%DEPC is supplied 20 μ l (each 3 multiple holes).The employing two-step method is carried out: stage 1:95 ℃, and 30s; Stage 2:95 ℃, 5s; 60 ℃, 30s (40cycles); Stage 3:60-95 ℃, every 30s gathers the first order fluorescence signal and makes melting curve.
The result shows, along with the increase of drug level, and the expression showed increased of P21/P27mRNA, and the downward modulation of the mRNA ratio of Bcl-2/Bax shows H
168Thereby can suppress the B16F10 cell proliferation by the expression that influences these mRNA, induce its apoptosis (Fig. 3).
Conclusion: this product can suppress the propagation of B16F10 melanoma cell, induces its apoptosis simultaneously.
Sequence table
SEQUENCE?LISTING
＜110〉Nanjing University of Traditional Chinese Medicine
＜120〉application of ligustrazine derivant in preparation treatment melanoma medicine
＜130〉do not have
<140>201110083088.4
<141>2011-04-02
<160>10
<170>PatentIn?version?3.3
<210>1
<211>20
<212>RNA
＜213〉artificial sequence
<220>
<221>P21(F)mRNA
<222>(1)..(20)
<223>n＝T
<220>
<221>misc_feature
<222>(3)..(3)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(5)..(5)
<223>nis?a，c，g，or?u
<220>
<221>misc_feature
<222>(10)..(10)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(13)..(13)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(15)..(15)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(17)..(18)
<223>n?is?a，c，g，or?u
<400>1
agnangccgn?cgncngnncg 20
<210>2
<211>20
<212>RNA
＜213〉artificial sequence
<220>
<221>P21(R)mRNA
<222>(1)..(20)
<223>n＝T
<220>
<221>misc_feature
<222>(4)..(4)
<223>n?is?a，c，g，or?u
<400>2
gagngcaaga?cagcgacaag 20
<210>3
<211>18
<212>RNA
＜213〉artificial sequence
<220>
<221>P27(F)mRNA
<222>(1)..(18)
＜223〉the 4th n=C ', the 5th n=I, all the other n=T
<220>
<221>misc_feature
<222>(4)..(6)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(14)..(15)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(17)..(17)
<223>n?is?a，c，g，or?u
<400>3
cagnnngccc?gagnnana 18
<210>4
<211>18
<212>RNA
＜213〉artificial sequence
<220>
<221>P27(R)mRNA
<222>(1)..(18)
<223>n＝T
<220>
<221>misc_feature
<222>(1)..(1)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(11)..(11)
<223>.n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(13)..(13)
<223>n?is?a，c，g，or?u
<400>4
nggggaaccg?ncngaaac 18
<210>5
<211>21
<212>RNA
＜213〉artificial sequence
<220>
<221>Bcl-2(F)mRNA
<222>(1)..(21)
<223>n＝T
<220>
<221>misc_feature
<222>(2)..(2)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(7)..(7)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(12)..(12)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(19)..(20)
<223>n?is?a，c，g，or?u
<400>5
anggggngaa?cngggggann?g 21
<210>6
<211>24
<212>RNA
＜213〉artificial sequence
<220>
<221>Bcl-2(R)mRNA
<222>(1)..(24)
<223>n＝T
<220>
<221>misc_feature
<222>(1)..(2)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(8)..(10)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(12)..(14)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(23)..(23)
<223>n?is?a，c，g，or?u
<400>6
nnccgaannn?gnnnggggca?ggnc 24
<210>7
<211>21
<212>RNA
＜213〉artificial sequence
<220>
<221>Bax(F)mRNA
<222>(1)..(21)
<223>n＝T
<220>
<221>misc_feature
<222>(4)..(4)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(7)..(8)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(13)..(16)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(18)..(18)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(21)..(21)
<223>n?is?a，c，g，or?u
<400>7
gggnggnngc?ccnnnncnac?n 21
<210>8
<211>20
<212>RNA
＜213〉artificial sequence
<220>
<221>Bax(R)mRNA
<222>(1)..(20)
<223>n＝T
<220>
<221>misc_feature
<222>(12)..(12)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(17)..(17)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(19)..(19)
<223>n?is?a，c，g，or?u
<400>8
cccggaggaa?gnccagngnc 20
<210>9
<211>20
<212>RNA
＜213〉artificial sequence
<220>
<221>β-actin(F)mRNA
<222>(1)..(20)
<223>n＝T
<220>
<221>misc_feature
<222>(1)..(1)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(5)..(5)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(10)..(10)
<223>n?is?a，c，g，or?u
<400>9
ngcgngacan?caaagagaag 20
<210>10
<211>19
<212>RNA
＜213〉artificial sequence
<220>
<221>β-actin(R)mRNA
<222>(1)..(19)
<223>n＝T
<220>
<221>misc_feature
<222>(3)..(3)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(13)..(14)
<223>n?is?a，c，g，or?u
<220>
<221>misc_feature
<222>(18)..(18)
<223>n?is?a，c，g，or?u
<400>10
gangccacag?gannccana 19
Claims (1)
1.2,5-dihydroxymethyl-3, the application of 6-dimethyl pyrazine in the preparation antitumor drug, described tumor is a malignant melanoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110083088A CN102204913B (en) | 2011-04-02 | 2011-04-02 | Application of ligustrazine derivative in preparation of medicament for treating melanoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110083088A CN102204913B (en) | 2011-04-02 | 2011-04-02 | Application of ligustrazine derivative in preparation of medicament for treating melanoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102204913A true CN102204913A (en) | 2011-10-05 |
| CN102204913B CN102204913B (en) | 2012-09-19 |
Family
ID=44694158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110083088A Expired - Fee Related CN102204913B (en) | 2011-04-02 | 2011-04-02 | Application of ligustrazine derivative in preparation of medicament for treating melanoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102204913B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301132A (en) * | 2013-07-03 | 2013-09-18 | 南京中医药大学 | Ligustrazine secondary-alcohol and tertiary-alcohol derivative and application for same in pharmacy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704433A (en) * | 2004-05-28 | 2005-12-07 | 北京理工大学 | Aldehydic acids tetramethylpyrazine ester and method for preparing same |
| CN101134764A (en) * | 2007-10-18 | 2008-03-05 | 重庆医科大学 | Method for synthesizing target compound-ligustrazine derivant preventing cerebrovascular disease |
| CN101361740A (en) * | 2008-09-25 | 2009-02-11 | 南京中医药大学 | Pharmacy use of 2,5- bis (hydroxymethyl)-3,6-dimethyl pyrazine and derivates thereof |
-
2011
- 2011-04-02 CN CN201110083088A patent/CN102204913B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704433A (en) * | 2004-05-28 | 2005-12-07 | 北京理工大学 | Aldehydic acids tetramethylpyrazine ester and method for preparing same |
| CN101134764A (en) * | 2007-10-18 | 2008-03-05 | 重庆医科大学 | Method for synthesizing target compound-ligustrazine derivant preventing cerebrovascular disease |
| CN101361740A (en) * | 2008-09-25 | 2009-02-11 | 南京中医药大学 | Pharmacy use of 2,5- bis (hydroxymethyl)-3,6-dimethyl pyrazine and derivates thereof |
Non-Patent Citations (2)
| Title |
|---|
| LIAN, XIAOJIE ET AL: "The application with tetramethyl pyrazine for antithrombogenicity improvement on silk fibroin surface", 《APPLIED SURFACE SCIENCE》, vol. 155, no. 2, 29 February 2008 (2008-02-29), pages 480 - 482 * |
| 刘锦荣等: "川芎嗪抗肿瘤转移作用及其机理研究", 《四川生理科学杂志》, vol. 12, no. 12, 28 February 1990 (1990-02-28), pages 31 - 32 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301132A (en) * | 2013-07-03 | 2013-09-18 | 南京中医药大学 | Ligustrazine secondary-alcohol and tertiary-alcohol derivative and application for same in pharmacy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102204913B (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Songia et al. | Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. | |
| Wei et al. | Cordycepin inhibits drug-resistance non-small cell lung cancer progression by activating AMPK signaling pathway | |
| CN105801467A (en) | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heterapahanes and meatllocenes useful for treating HCV infections | |
| Bojarczuk et al. | B-cell receptor signaling in the pathogenesis of lymphoid malignancies | |
| Kim et al. | 5′-Nitro-indirubinoxime, an indirubin derivative, suppresses metastatic ability of human head and neck cancer cells through the inhibition of Integrin β1/FAK/Akt signaling | |
| US20190175499A1 (en) | Use of chlorogenic acid in preparing pharmaceuticals for treatment of lag-3-mediated disease | |
| CN111467345B (en) | Application of dexamethasone, rosiglitazone and 3-isobutyl-1-methylxanthine composition in preparing medicine for inhibiting growth and metastasis of ovarian cancer cells induced by cobalt chloride | |
| CN103298475A (en) | Design of oligonucleotide analogs as therapeutic agents | |
| He et al. | Atractylodin may induce ferroptosis of human hepatocellular carcinoma cells | |
| CN108913662A (en) | A kind of method of the functional high-throughput medication screening of lung cancer | |
| CN103304635A (en) | Application of cyclopeptide compound for preventing tumors and preparation method of compound | |
| CN102204913B (en) | Application of ligustrazine derivative in preparation of medicament for treating melanoma | |
| Sun et al. | Effects of AZT and RNA-protein complex (FA-2-b-β) extracted from Liang Jin mushroom on apoptosis of gastric cancer cells | |
| CN107903210B (en) | Small molecule inhibitor SLD4650 and application thereof in pharmacy | |
| CN112656827B (en) | Radix araliae armatae total saponin and application thereof in preparation of medicine for treating restenosis after vascular injury | |
| CN104706649A (en) | Application of oroxyloside to preparation of anti-tumor drugs | |
| CN113384591B (en) | Combined drug of trametes acid and sorafenib and application of combined drug in preparation of antitumor drug | |
| Nardin et al. | The uleine-rich fraction of Himatanthus lancifolius blocks proliferative responses of human lymphoid cells | |
| CN106389764B (en) | A kind of Chinese materia medica preparation and its preparation and application | |
| CN104873515B (en) | The application of acute leukemia FLT3 ITD being mutated for Buddhist nun according to Shandong | |
| CN109908144B (en) | Application of isoliensinine in preparation of drugs for targeted inhibition of AKT activation | |
| CN113995753A (en) | Application of Chinese medicinal molecular sophocarpine in preparing medicament for treating glioblastoma | |
| CN103417988B (en) | CDK2 gene is preparing the application in Induction Therapy of Leukemia medicine | |
| Dong et al. | Natural killer cell activating receptor NKG2D is involved in the immunosuppressive effects of mycophenolate mofetil and hepatitis B virus infection | |
| CN107879997B (en) | Small molecule inhibitor SLD1338 and application thereof in pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120919 Termination date: 20150402 |
|
| EXPY | Termination of patent right or utility model |